EZH2 and Burkitt lymphoma: Furthermore, expression levels of EZH2 and c-MYC in liver tissue were reduced in the dEZH2-treated group compared to control, suggesting that dEZH2 maintains EZH2 degradation activity in vivo and effectively inhibits the progression of Burkitt’s lymphoma (Figure 4D).